No Data
No Data
No Data
No Data
No Data
Earnings Call Summary | Nanobiotix(NBTX.US) Q4 2023 Earnings Conference
The following is a summary of the Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript:Financial Performance:Nanobiotix entered into a $2.5 billion license agreement with Johnson Pharmaceutical in
Futu NewsApr 28 00:11 · Conference Call
Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Good day and welcome to the Nanobiotix Business Update and Full-Year 2023 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.
Earnings Call TranscriptsApr 27 23:51
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership
TipRanksApr 26 14:01
Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) p
BenzingaApr 25 05:42
Nanobiotix Sa ADR Reports Promising 2023 Progress
TipRanksApr 25 05:27
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Dow JonesApr 25 04:41
No Data
No Data